Neupro® - Restless Legs Syndrome | UCB
UCB's Global Corporate Website

Neupro® - Restless Legs Syndrome

Europe

In Europe, Neupro® is indicated for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in adults.

Prescribing information Europe

USA

In the US, Neupro® (Rotigotine Transdermal System) is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome.

Other countries

For availability of Neupro® in other countries, please consult our local websites.